CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Facet Biotech Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Facet Biotech Corporation
1400 Seaport Boulevard
Phone: (650) 454-1000p:650 454-1000 Redwood, CA  94063  United States Ticker: FACTFACT

This company was Merged or Acquired on 4/21/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Facet Biotech Corporation (Facet Biotech) is a biotechnology company dedicated to advancing its pipeline of several clinical-stage products and expanding and deriving value from its protein engineering platform technologies to improve the clinical performance of protein therapeutics. The Company has a range of investigational compounds in stages of development for the treatment of cancer and immunologic diseases, four of which it is developing with its collaboration partners: two with Biogen Idec Inc. (Biogen Idec), one with Bristol-Myers Squibb Company (BMS) and one with Trubion Pharmaceuticals, Inc. (Trubion). Facet Biotech’s developing products include Daclizumab, Volociximab (M200), Elotuzumab (HuLuc63), TRU-016, PDL192 and PDL241. In April 2010, Abbott Laboratories completed its acquisition of Facet Biotech Corporation.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/200912/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Financial Officer, Senior Vice President Andrew L.Guggenhime 41 12/9/2008 12/9/2008
Senior Vice President, Chief Scientific Officer MarkRolfe 50 8/1/2009 8/1/2009
Senior Vice President - Commercial and Corporate Development TedLlana 46 1/12/2009 1/12/2009
4 additional Officers and Directors records available in full report.

Business Names
Business Name
FACT
Fremont Holding L.L.C.
Fremont Management, Inc.

General Information
Number of Employees: 189 (As of 12/31/2009)
Outstanding Shares: 25,093,117 (As of 2/15/2010)
Shareholders: 156
Stock Exchange: NASD
Federal Tax Id: 263070657


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023